Celmatix, a biotechnology company focused on helping physicians guide patients to treatments that maximize their personal reproductive potential, has announced six research presentations at the annual meeting of the American Society for Reproductive Medicine (ASRM), held in Boston. Among the data presented was a new study suggesting that up to 25 percent of patients may be discontinuing assisted reproductive therapies such as in vitro fertilization (IVF) early, while they still have a good chance of having a baby...
No comments:
Post a Comment